Related Experiment Video
Updated: Apr 3, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Left atrial appendage occlusion for stroke prevention
Insights
Atrial fibrillation (AF) increases stroke risk due to clots forming in the left atrial appendage (LAA). LAA occlusion offers an alternative to anticoagulation for stroke prevention in AF patients.
Area of Science:
- Cardiology
- Vascular Medicine
- Interventional Cardiology
Background:
- Atrial fibrillation (AF) is a common arrhythmia linked to thromboembolic stroke.
- The left atrial appendage (LAA) is a primary source of thrombus formation in AF.
- Current anticoagulation therapies carry bleeding risks.
Purpose of the Study:
- To review the role of the LAA in AF-related thromboembolism.
- To discuss device and surgical LAA occlusion therapies.
- To evaluate current clinical data on LAA occlusion for stroke prevention.
Main Methods:
- Literature review of studies on LAA and thromboembolism in AF.
- Analysis of clinical data for LAA occlusion devices and surgical techniques.
- Examination of evidence supporting LAA closure for stroke prevention.
Main Results:
- The LAA is a significant contributor to stroke in AF patients.
- LAA occlusion is an emerging alternative to anticoagulation.
- Clinical data supports the efficacy of LAA closure devices.
Conclusions:
- LAA occlusion is a viable strategy for stroke risk reduction in AF.
- Device-based and surgical LAA closure offer alternatives to anticoagulation.
- Further research and clinical adoption of LAA occlusion are warranted.
Abstract:
Atrial fibrillation (AF) remains the most common arrhythmia encountered in clinical practice. One of its more common deleterious effects is the development of thromboembolism leading to stroke. The left atrial appendage (LAA) has been shown to the site of the majority of thrombus formation leading to stroke. Anticoagulation with warfarin has been the treatment of choice for prevention of embolic events. Newer anticoagulants have been developed but they still have the potential side effect of causing major bleeding. Occlusion of the LAA has emerged as an alternative therapeutic approach to medical therapy. The aim of this article is to discuss in detail the role of the LAA in thromboembolism in AF, role of device and surgical therapies, and the current clinical data supporting their use. This is particularly timely in that there is now an approved LAA closure device approved in the US for stroke prevention in patients with nonvalvular AF.
